Home › Trial NCT01954784
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
- Trial IDNCT01954784
- StatusTerminated
- PhasePhase 1
- Study typeInterventional
- SponsorCase Comprehensive Cancer Center
- Enrollment8
- Start date2013-10-07
- ConditionsRefractory Multiple Myeloma · Stage I Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.